Recro Pharma Inc (REPH) Expected to Post Quarterly Sales of $16.81 Million

Share on StockTwits

Equities research analysts forecast that Recro Pharma Inc (NASDAQ:REPH) will report sales of $16.81 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Recro Pharma’s earnings, with estimates ranging from $16.27 million to $17.40 million. Recro Pharma posted sales of $16.93 million during the same quarter last year, which suggests a negative year over year growth rate of 0.7%. The company is scheduled to announce its next quarterly earnings report on Thursday, August 9th.

On average, analysts expect that Recro Pharma will report full year sales of $70.88 million for the current fiscal year, with estimates ranging from $70.74 million to $71.10 million. For the next fiscal year, analysts forecast that the firm will report sales of $76.24 million per share, with estimates ranging from $69.10 million to $84.37 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Recro Pharma.

Recro Pharma (NASDAQ:REPH) last released its quarterly earnings data on Wednesday, May 9th. The specialty pharmaceutical company reported ($0.65) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $0.03. Recro Pharma had a negative return on equity of 105.78% and a negative net margin of 74.85%. The business had revenue of $19.54 million for the quarter, compared to analysts’ expectations of $17.32 million.

Several equities analysts have recently weighed in on the company. ValuEngine upgraded Recro Pharma from a “hold” rating to a “buy” rating in a report on Wednesday, April 18th. Berenberg Bank initiated coverage on Recro Pharma in a report on Thursday, April 19th. They set a “buy” rating on the stock. Zacks Investment Research upgraded Recro Pharma from a “sell” rating to a “hold” rating in a research note on Wednesday, March 21st. Oppenheimer restated a “buy” rating on shares of Recro Pharma in a research note on Friday, March 23rd. Finally, BidaskClub upgraded Recro Pharma from a “hold” rating to a “buy” rating in a research note on Thursday, May 24th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $12.63.

Recro Pharma opened at $5.18 on Thursday, Marketbeat reports. Recro Pharma has a fifty-two week low of $5.00 and a fifty-two week high of $13.05. The company has a current ratio of 1.78, a quick ratio of 1.55 and a debt-to-equity ratio of 2.20. The stock has a market cap of $108.28 million, a PE ratio of -2.60 and a beta of -0.97.

In other Recro Pharma news, major shareholder Healthcare Master Fun Broadfin sold 188,000 shares of the business’s stock in a transaction that occurred on Thursday, May 24th. The stock was sold at an average price of $5.81, for a total value of $1,092,280.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 20.90% of the company’s stock.

Several large investors have recently bought and sold shares of REPH. Schwab Charles Investment Management Inc. increased its position in shares of Recro Pharma by 166.5% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 81,269 shares of the specialty pharmaceutical company’s stock worth $752,000 after purchasing an additional 50,769 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Recro Pharma by 115.6% during the 4th quarter. Wells Fargo & Company MN now owns 52,848 shares of the specialty pharmaceutical company’s stock worth $489,000 after purchasing an additional 28,340 shares during the last quarter. BlackRock Inc. increased its position in shares of Recro Pharma by 1.4% during the 4th quarter. BlackRock Inc. now owns 1,011,855 shares of the specialty pharmaceutical company’s stock worth $9,359,000 after purchasing an additional 13,799 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Recro Pharma by 23.4% during the 4th quarter. Renaissance Technologies LLC now owns 122,000 shares of the specialty pharmaceutical company’s stock worth $1,129,000 after purchasing an additional 23,100 shares during the last quarter. Finally, Deutsche Bank AG increased its position in shares of Recro Pharma by 141.6% during the 4th quarter. Deutsche Bank AG now owns 30,446 shares of the specialty pharmaceutical company’s stock worth $281,000 after purchasing an additional 17,845 shares during the last quarter. 56.15% of the stock is currently owned by hedge funds and other institutional investors.

About Recro Pharma

Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Get a free copy of the Zacks research report on Recro Pharma (REPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply